Approximately 60% of the patients with Parkinson's Disease (PD) that receive Levodopa therapy eventually develop response fluctuations in motor symptoms, such as rigidity, freezing and akinesia. Patients experience an 'off'-period just before the next dose of dopaminergic medication is needed, called the 'wearing-off'-phenomena. Wearing-off is also accompanied by non-motor symptoms such as depression, anxiety, pain and thinking disability. Together, these motor and non-motor symptoms have a major impact on the quality of life of patients and their partner or caregiver. Patients with wearing-off often experience severe anxiety and panic symptoms that are incongruent with the severity of the motor symptoms during an 'off' period. These symptoms include stress, dizziness, pounding/racing of the heart, dyspnoea and hyperventilation. This type of anxiety is called wearing-off related anxiety (WRA) and might be a consequence of the hypersensitivity towards somatic manifestations and effects of a wearing-off period. This bodily misperception can have major consequences for the patient's feelings and behaviour. The experienced anxiety is often not consciously linked to the wearing-off and is therefore not well recognized by neurologists. Treatment as usual in response fluctuations is physiotherapy, consisting of physical exercises for mobility problems, freezing, dyskinesias, etc. This kind of training hardly touches upon the mental aspects and the role of anxiety as integral element of the response fluctuations. Cognitive behaviour therapy (CBT, including exposure in vivo) is sometimes used to treat WRA, but seems to have unsatisfactory results since the changed body awareness is not sufficiently addressed. Also, the methods used in cognitive therapies focus on the elimination of WRA which is often not realistic since wearing-off symptoms will remain or even increase during disease progression. As of yet, there are no known alternative intervention options. This study focuses on a new intervention by integrating elements from physiotherapy, mindfulness, CBT (mainly exposure), Acceptance and Commitment Therapy (ACT) and psycho-education. Objective: The current proposal aims at investigating the effect of a multidisciplinary non-verbal intervention on the awareness and modulation of WRA to improve self-efficacy, mobility, mood, and quality of life as compared to usual care. Study design: Randomized controlled clinical trial. Study population: Thirty-six PD patients who experience WRA. Intervention: Patients with PD are randomly allocated into one of two groups (n= 18 each). One group receives the experimental 'body-awareness therapy', while the second group receives regular group-physiotherapy (treatment as usual). Both interventions will take 6 weeks in which 2 sessions per week with a duration of 1,5 hour will be performed. Main study parameters/endpoints: The General Self-Efficacy Scale is the primary outcome measure and will be assessed prior to, directly after and 18 weeks after the intervention.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
36
Experimental condition: BEWARE training group The physical and psychosocial elements of the training sessions will be complementary: psychological techniques are used to induce and endure wearing-off and physical techniques are used to improve body awareness to cope with the off-periods. Specifically the following techniques will be applied: 1. Body scan 2. Psychoeducation 3. Acceptance Commitment Therapy / Mindfulness skills (sustained attention, concentration, non-reactivity, nonjudging of experience) 4. Body Awareness Training 5. Exposure training (imaginary exposure to induce response fluctuations) 6. Training in cueing techniques to overcome problems with initiation and freezing 7. Visual Feedback training 8. Relaxation techniques
Control condition: Treatment as Usual The control group will receive treatment as usual based on the current guidelines for physical therapy in patients with Parkinson's Disease, with the same training schedule of 2x per week for 1,5 hours during 6 weeks. Group treatment will contain exercises for balance, walking, posture, transfers, arm/hand dexterity, strength, flexibility, relaxation and physical condition.
VU Medical Center
Amsterdam, North Holland, Netherlands
Self-efficacy
how the patients can live their lives without being controlled by their disease, measured with the General Self Efficacy Scale
Time frame: Change from baseline in self-efficacy at 6 weeks
Self-efficacy
how the patients can live their lives without being controlled by their disease, measured with the General Self Efficacy Scale
Time frame: Change from baseline in self-efficacy at 18 weeks
Anxiety
measured with the Beck Anxiety Inventory
Time frame: Change from baseline in anxiety at 6 weeks
Depression
measured with the Beck Depression Inventory
Time frame: Change from baseline in depression at 6 weeks
Balance performance
measured with the One Leg Stance test
Time frame: Change from baseline in balance performance at 6 weeks
comfortable walking speed
measured with the 10 Meter Walk Test
Time frame: Change from baseline in walking speed at 6 weeks
Quality of life
measured with the Parkinson's Disease Questionnaire - 39
Time frame: Change from baseline in quality of life at 6 weeks
Wearing-off symptoms
Assessing wearing-off related symptoms with the Wearing-off Questionnaire - 19
Time frame: Change from baseline in wearing-off symptoms at 6 weeks
Activities of Daily Living independence
measured with the Nottingham Extended Activities of Daily Living index
Time frame: Change from baseline in independence at 6 weeks
Freezing of Gait
To asses an important symptom of Parkinson's disease, we included the Freezing of Gait Questionnaire
Time frame: Change from baseline in freezing of gait at 6 weeks
Anxiety
measured with the Beck Anxiety Inventory
Time frame: Change from baseline in anxiety at 18 weeks
Depression
measured with the Beck Depression Inventory
Time frame: Change from baseline in depression at 18 weeks
Balance performance
measured with the One Leg Stance Test
Time frame: Change from baseline in balance performance at 18 weeks
Comfortable walking speed
measured with the 10 Meter Walk Test
Time frame: Change from baseline in walking speed at 18 weeks
Quality of Life
measured with the Parkinson's Disease Questionnaire - 39
Time frame: Change from baseline in quality of life at 18 weeks
Wearing-off symptoms
assessing wearing-off related symptoms with the Wearing-Off Questionnaire - 19
Time frame: Change from baseline in anxiety at 6 weeks
Activities of Daily Living independence
measured with the Nottingham Extended Activities of Daily Living index
Time frame: Change from baseline in independence at 18 weeks
Freezing of gait
to assess an important symptom of Parkinson's Disease, as measured by the freezing of gait questionnaire
Time frame: Change from baseline in freezing of gait at 18 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.